Sernova Biotherapeutics Inc
SEOVF
$0.146
$0.00382.67%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.87% | 5.29% | 9.85% | 5.36% | 27.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.03% | -22.39% | 3.22% | 26.35% | 46.36% |
| Operating Income | 38.03% | 22.39% | -3.22% | -26.35% | -46.36% |
| Income Before Tax | 32.18% | 18.08% | -8.34% | -29.97% | -46.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.15% | 18.07% | -8.34% | -29.97% | -46.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.15% | 18.07% | -8.34% | -29.97% | -46.99% |
| EBIT | 38.03% | 22.39% | -3.22% | -26.35% | -46.36% |
| EBITDA | 38.27% | 22.63% | -3.41% | -26.94% | -47.15% |
| EPS Basic | 33.60% | 18.49% | -8.75% | -27.40% | -39.41% |
| Normalized Basic EPS | 33.76% | 18.62% | -8.64% | -27.22% | -39.46% |
| EPS Diluted | 33.60% | 18.49% | -8.75% | -27.40% | -39.41% |
| Normalized Diluted EPS | 33.76% | 18.62% | -8.64% | -27.22% | -39.46% |
| Average Basic Shares Outstanding | 3.18% | 1.19% | -0.22% | 2.54% | 6.20% |
| Average Diluted Shares Outstanding | 3.18% | 1.19% | -0.22% | 2.54% | 6.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |